Altamira Therapeutics Ltd (CYTO) Stock
CYTO is no longer traded. Altamira Therapeutics was delisted from the Nasdaq in December 2024.
Prices on this page are historical; the last trade was December 20, 2024 at $0.12.
Altamira Therapeutics stock price history
CYTO final trading statistics
- Final close
- $0.12
- Final trading day
- Dec 20, 2024
- Market cap at delisting
- $1.13M
- Shares outstanding
- 3.78M
- Final 52-week range
- $0.10 – $3.60
- Avg. volume (final 3 mo.)
- 134,383
- All-time high (split-adj.)
- $623200.00 · Jan 2016
- All-time low (split-adj.)
- $0.12 · Dec 2024
- Return since IPO
- -100.0%
- Beta
- 2.44
- Book value / share
- $2.37
- Price / book
- 0.05
Altamira Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$7.3M | — |
| FY2022 | $305.6K | -$26.5M | — |
| FY2021 | $63.9K | -$17.4M | — |
| FY2020 | $174.5K | -$8.2M | -$1.42 |
| FY2019 | -$56.0K | -$6.6M | -$1.15 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Altamira Therapeutics stock FAQ
What happened to Altamira Therapeutics stock?
Altamira Therapeutics stock was delisted from the Nasdaq. Its final close was $0.12 on December 20, 2024.
Is CYTO stock still trading?
No. CYTO was delisted from the Nasdaq in December 2024 and no longer trades on a U.S. exchange.
What was the last price of CYTO stock?
CYTO closed at $0.12 on its final trading day, December 20, 2024, for a market value of about $1.13M.
What were Altamira Therapeutics's revenue and earnings in its last full fiscal year?
Altamira Therapeutics reported revenue of $0.00 and net income of -$7.3M in fiscal 2023, its last full year as a public company.
When did Altamira Therapeutics go public?
Altamira Therapeutics Ltd stock began trading on August 6, 2014.